These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33323761)

  • 1. Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates.
    Warnes TW; Roberts SA; Smith A; Cope VM; Vales P; Haboubi NY; McMahon RF
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(12):1595-1602. PubMed ID: 33323761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy.
    Abraham SC; Kamath PS; Eghtesad B; Demetris AJ; Krasinskas AM
    Am J Surg Pathol; 2006 Nov; 30(11):1454-61. PubMed ID: 17063088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precirrhotic Primary Biliary Cholangitis with Portal Hypertension: Bile Duct Injury Correlate.
    Hu YF; Li SX; Liu HL; Du ZX; Wang SS; Chen MY; Wang L; Xiong QF; Zhong YD; Liu DX; Yang YF
    Gut Liver; 2024 Sep; 18(5):867-876. PubMed ID: 38623061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis.
    Colina F; Pinedo F; Solís JA; Moreno D; Nevado M
    Gastroenterology; 1992 Apr; 102(4 Pt 1):1319-24. PubMed ID: 1551537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic hemodynamics in 24 patients with nodular regenerative hyperplasia and symptomatic portal hypertension.
    Bissonnette J; Généreux A; Côté J; Nguyen B; Perreault P; Bouchard L; Pomier-Layrargues G
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1336-40. PubMed ID: 22554152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Portal hypertension in primary biliary cirrhosis. Relationship with histological features.
    Navasa M; Parés A; Bruguera M; Caballería J; Bosch J; Rodés J
    J Hepatol; 1987 Dec; 5(3):292-8. PubMed ID: 3429837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis.
    Rodrigues SG; Montani M; Guixé-Muntet S; De Gottardi A; Berzigotti A; Bosch J
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2101-2109.e1. PubMed ID: 30625404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Portal pressure is of significant prognostic value in primary biliary cholangitis.
    Warnes TW; Roberts SA; Smith A; Cope VM; Vales P; McMahon R
    Liver Int; 2023 Jan; 43(1):139-146. PubMed ID: 35622445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
    Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
    J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cirrhotic portal hypertension (obliterative portal venopathy) is the predominant form of chronic liver disease in cystic fibrosis.
    ONeill JP; Clifford CS; Nolan NP; McCormick PA
    Ir J Med Sci; 2023 Aug; 192(4):1657-1660. PubMed ID: 36114932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.
    Schwabl P; Mandorfer M; Steiner S; Scheiner B; Chromy D; Herac M; Bucsics T; Hayden H; Grabmeier-Pfistershammer K; Ferlitsch A; Oberhuber G; Trauner M; Peck-Radosavljevic M; Reiberger T
    Aliment Pharmacol Ther; 2017 Jan; 45(1):139-149. PubMed ID: 27910154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic Venous Pressure Gradient Measurements in Children: Correlation With Hepatic Histology and Clinical Indicators of Portal Hypertension.
    Ebel NH; Carlin K; Shaffer ML; Shivaram G; Hawkins M; Lane ER; Cooper K; Lindquester WS; Gadodia G; Murray KF
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):788-792. PubMed ID: 30921261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value.
    Zhang Y; Lai H; Chen J; Lai R; Lin X; Lin S; Liu B; Lin Q; Wang B; Zheng Q
    Ann Hepatol; 2024 Sep; 30(1):101577. PubMed ID: 39276989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A; Teml A; Reinisch W; Ulbrich G; Wrba F; Homoncik M; Gangl A; Peck-Radosavljevic M; Vogelsang H
    Am J Gastroenterol; 2007 Nov; 102(11):2495-503. PubMed ID: 17894846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common variable immunodeficiency disorder (CVID)-related liver disease: assessment of the main histological aspects using novel semiquantitative scoring systems, image analysis and correlation with clinical parameters of liver stiffness and portal hypertension.
    Silva H; Brito CGX; Hall A; Eden N; Somers H; Burke N; Burns SO; Lowe D; Thorburn D; Halliday N; Quaglia A
    J Clin Pathol; 2024 Sep; 77(10):709-716. PubMed ID: 37553247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic venous pressure gradient measurement: time to learn!
    Kumar A; Sharma P; Sarin SK
    Indian J Gastroenterol; 2008; 27(2):74-80. PubMed ID: 18695309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of hepatic steatosis on portal hypertension.
    Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T
    PLoS One; 2019; 14(11):e0224506. PubMed ID: 31693695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
    Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
    Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.